Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20417073 | 0.91 | KLKB1 (0.39) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL30401933 | 0.91 | KLKB1 (0.39) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20436698 | 0.88 | KLKB1 (0.38) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20436700 | 0.88 | KLKB1 (0.38) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20400627 | 0.88 | ADORA2A (0.49) | ADORA2BADORA2AADORA1 | |
| SCHEMBL30401511 | 0.88 | ADORA2A (0.49) | ADORA2BADORA2AADORA1 | |
| SCHEMBL20416723 | 0.88 | CYP19A1 (0.43) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20436702 | 0.86 | LRRK2 (0.37) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20417082 | 0.86 | CTSS (0.50) | KLKB1CYP19A1HDAC6HDAC2HDAC8 | |
| SCHEMBL20416734 | 0.85 | CYP19A1 (0.41) | KLKB1CYP19A1HDAC6HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | KLKB1 1782/4885CYP19A1 1735/4885HDAC6 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.